May 24, 2022
A 2 mg version of Novo Nordisk’s diabetes drug Ozempic (semaglutide), which has been hit by supply disruptions, and Nichi-Iko Pharmaceutical’s Avastin (bevacizumab) biosimilar will join the NHI price list in Japan on May 25, according to the government’s official...read more